Synairgen (LON:SNG) Shares Down 16% – Time to Sell?

Synairgen plc (LON:SNG) shares traded down 16% during mid-day trading on Monday . The stock traded as low as GBX 0.73 ($0.01) and last traded at GBX 0.79 ($0.01). 920,817 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 1,456,314 shares. The stock had previously closed at GBX 0.93 ($0.01).

Synairgen Trading Down 16.0 %

The company has a 50 day moving average price of GBX 1.97 and a 200-day moving average price of GBX 3.29. The company has a market cap of £7.68 million, a P/E ratio of -0.47 and a beta of -2.23.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).